Plan B vs Abortion Pills, Know the Difference

A once-promising HIV vaccine candidate is dead in the water after a major human trial showed it worked no better than the placebo, Bhekisisa reports.
The drug was a reformulated version of a vaccine that tested 31% effective in a Thailand study—modest results, but good enough to warrant further study. Hoping to achieve 50% effectiveness, researchers reworked the drug to tackle a form of HIV ubiquitous in South Africa—where nearly a fifth of adults are infected, The Washington Post reports
This was the 7th major trial of an HIV vaccine—2 more are underway.
So, what now? Until a successful vaccine arrives, promoting pre-exposure prophylaxis (PrEP) is governments’ best bet for curbing the disease, says Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, which funded the research with the Gates Foundation.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top